Anixa Biosciences announces first three-month stable disease in ovarian cancer CAR-T trial
ANIX•Anixa Biosciences reported the first patient in the current ovarian cancer CAR-T trial cohort had no cancer progression three months after treatment; multiple trial patients have survived more than a year, and no dose-limiting toxicities have been observed to date.
1. Trial update
Anixa Biosciences said the first patient in the current cohort showed no cancer progression three months after treatment. The company also said multiple patients have survived more than one year, including one beyond two years, and no dose-limiting toxicities have been observed to date.
